Medpace (NASDAQ:MEDP) CEO Sells $13,739,074.02 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 21,966 shares of the stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the completion of the transaction, the chief executive officer directly owned 338,225 shares of the company’s stock, valued at approximately $211,549,590.75. The trade was a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Medpace Stock Performance

MEDP stock opened at $599.47 on Friday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm has a market capitalization of $16.73 billion, a price-to-earnings ratio of 35.14, a PEG ratio of 2.67 and a beta of 1.18. The firm has a 50 day moving average price of $599.95 and a 200-day moving average price of $521.18.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the previous year, the company earned $3.10 earnings per share. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MEDP shares. Barclays set a $600.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Robert W. Baird lifted their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. BMO Capital Markets boosted their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday, July 24th. Finally, Leerink Partners set a $620.00 target price on shares of Medpace in a report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $602.27.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: UBS upgraded Medpace from “sell” to “hold” and raised its price target to $673 from $405. The new target is above recent trading levels, suggesting UBS sees reduced downside risk. UBS upgrades Medpace and raises price target
• Positive Sentiment: Medpace’s latest quarterly results remain supportive of its growth story: revenue rose 17.2% year over year to $707.3 million, while earnings of $4.25 per share exceeded the $3.98 consensus estimate. Fiscal 2026 earnings guidance also remains intact.
• Neutral Sentiment: Analyst sentiment is broadly mixed, with most firms maintaining “hold” ratings. The consensus price target is approximately $602.27, close to recent levels, indicating that much of the company’s growth may already be reflected in its valuation.
• Negative Sentiment: CEO August Troendle sold 21,966 shares for approximately $13.7 million on September 30, after selling 26,701 shares worth about $16.6 million on September 29. The combined sales totaled roughly $30.3 million and materially reduced his direct ownership. Additional smaller sales were also reported, raising concerns about insider confidence and contributing to the stock’s weakness. Troendle nevertheless retains a substantial stake. Medpace CEO stock sale SEC filing

Institutional Investors Weigh In On Medpace

A number of large investors have recently bought and sold shares of MEDP. Johnson Financial Group Inc. purchased a new position in Medpace during the 2nd quarter worth approximately $27,000. Jones Financial Companies Lllp acquired a new position in Medpace during the second quarter valued at $30,000. Allied Private Wealth LLC acquired a new position in Medpace during the second quarter valued at $31,000. Kilter Group LLC purchased a new stake in Medpace in the second quarter valued at $31,000. Finally, Basecamp Wealth Advisors LLC boosted its holdings in Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.